U.S. flag

An official website of the United States government

NM_000199.5(SGSH):c.1135del (p.Val379fs) AND Sanfilippo syndrome

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Jun 14, 2016
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000266557.6

Allele description [Variation Report for NM_000199.5(SGSH):c.1135del (p.Val379fs)]

NM_000199.5(SGSH):c.1135del (p.Val379fs)

Gene:
SGSH:N-sulfoglucosamine sulfohydrolase [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
17q25.3
Genomic location:
Preferred name:
NM_000199.5(SGSH):c.1135del (p.Val379fs)
HGVS:
  • NC_000017.11:g.80210826del
  • NG_008229.1:g.14575del
  • NG_032778.1:g.45835del
  • NM_000199.5:c.1135delMANE SELECT
  • NM_001352921.3:c.*222del
  • NM_001352922.2:c.*185del
  • NP_000190.1:p.Val379fs
  • LRG_1330:g.45835del
  • NC_000017.10:g.78184625del
  • NM_000199.3:c.1135delG
  • NR_148201.2:n.1049del
Protein change:
V379fs
Links:
dbSNP: rs777956287
NCBI 1000 Genomes Browser:
rs777956287
Molecular consequence:
  • NM_001352921.3:c.*222del - 3 prime UTR variant - [Sequence Ontology: SO:0001624]
  • NM_001352922.2:c.*185del - 3 prime UTR variant - [Sequence Ontology: SO:0001624]
  • NM_000199.5:c.1135del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NR_148201.2:n.1049del - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:
Sanfilippo syndrome
Synonyms:
Mucopolysaccharidosis type III; Mucopoly-saccharidosis type 3; Mucopolysaccharidosis type 3; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0018937; MedGen: C0026706

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000407348Illumina Laboratory Services, Illumina
criteria provided, single submitter

(ICSL Variant Classification 20161018)
Pathogenic
(Jun 14, 2016)
germlineclinical testing

PubMed (4)
[See all records that cite these PMIDs]

ICSL_Variant_Classification_20161018.pdf

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.

Yogalingam G, Hopwood JJ.

Hum Mutat. 2001 Oct;18(4):264-81. Review.

PubMed [citation]
PMID:
11668611

Transport, enzymatic activity, and stability of mutant sulfamidase (SGSH) identified in patients with mucopolysaccharidosis type III A.

Muschol N, Storch S, Ballhausen D, Beesley C, Westermann JC, Gal A, Ullrich K, Hopwood JJ, Winchester B, Braulke T.

Hum Mutat. 2004 Jun;23(6):559-66.

PubMed [citation]
PMID:
15146460
See all PubMed Citations (4)

Details of each submission

From Illumina Laboratory Services, Illumina, SCV000407348.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (4)

Description

The c.1135delG (p.Val379CysfsTer34) variant (also known as delG1147) results in a frameshift, and is predicted to result in premature termination of the protein. The p.Val379CysfsTer variant has been identified in at least six patients with mucopolysaccharidosis type III, including one in a homozygous state and five in a compound heterozygous state (Weber et al. 1997; Muschol et al. 2004; Chistiakov et al. 2014). Control data are unavailable for this variant, which is not found in the 1000 Genomes Project, the Exome Sequencing Project, or the Exome Aggregation Consortium. Muschol et al. (2004) demonstrated that the p.Val379CysfsTer34 variant protein is degraded in the endoplasmic reticulum prior to the sorting site in the Golgi apparatus. In addition, Chistiakov et al. (2014) showed that the variant resulted in markedly reduced enzyme activity in patients compared to control levels. Patients who were compound heterozygous for the p.Val379CysfsTer34 variant and a common missense variant (p.Arg74Cys), had residual SGSH activity which was intermediate between the enzymatic activity in individuals who were homozygous for the p.Arg74Cys variant and those who were compound heterozygous for the p.Arg74Cys variant. Due to the potential impact of frameshift variants and the supporting evidence from the literature, the p.Val379CysfsTer34 variant is classified as pathogenic for mucopolysaccharidosis type III.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 20, 2024